Magnetic resonance imaging (MRI) of the brain, brain tumor

Niraparib for Newly Diagnosed Glioblastoma

About the Glioblastoma
clinical trial

The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 0 clinical trial to evaluate niraparib, a novel targeted therapy, in patients with newly diagnosed glioblastoma.

The goal of this Phase 0 study is to confirm that niraparib is capable of crossing the blood-brain barrier. Patients with positive results may advance to an expansion phase that combines therapeutic dosing of niraparib in combination with standard-of-care fractionated radiotherapy.

The expansion phase of this study will examine progression-free survival and monitor safety and tolerability of niraparib in combination with radiation.

  • PARP (poly ADP ribose polymerase) is a protein that plays an important role in cell survival response to DNA damage.
  • Niraparib (the treatment agent) is an oral, highly selective PARP inhibitor that blocks the tumor cell survival response.
  • Niraparib is approved by the FDA for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

Click here for information on the study of niraparib for recurrent glioma (grades II-IV) patients.

Glioblastoma Trial Details

Study Status

Recruiting

Treatment Agent(s)

Niraparib

Diseases

Newly Diagnosed Glioblastoma 

Estimated Enrollment

24 Participants 

Clinicaltrials.gov identifier
Patient and doctor reviewing chart

You may be eligible if:

  • You are 18 years or older
  • You have a suspected newly diagnosed glioblastoma
  • You plan on following the standard treatment regimen, including surgical resection and radiation

View all eligibility criteria by visiting ClinicalTrials.gov or call 602-406-8605 to speak with a patient navigator.

Phase 0 Clinical Trial: How it works

Icon of Brain Tumor Patient

Once enrolled, a patient receives a short exposure to the experimental therapy days before a planned operation to remove their tumor.


Glioblastoma Tumor Illustration

This exposure is enough that when we remove the tumor, our team of experts can answer an important question: Did the treatment penetrate the tumor? 


Combination Therapy for Gliboblastoma

If the drug penetrates the tumor at sufficient levels, the patient may move forward with receiving the treatment in combination with fractionated radiotherapy in the therapeutic expansion phase.


Stopwatch Timer

Alternatively, if the treatment has no effect on the tumor, the patient can enroll in another clinical trial without losing time or receiving ineffective treatment.


Am I Eligible?

Submit a free trial screening request today to learn if you may qualify for a clinical trial or talk to an Ivy Navigator by calling 602-406-8605.

Woman writing on a notepad

Open Clinical Trials

View More
Louise Hulme flexing

Patient Stories

Read Stories